Background. Statins are used to reduce cardiovascular disease risk. Recent studies suggest that statin use may be associated with an increased influenza risk among influenza vaccinees. We used Medicare data to evaluate associations between statins and risks of influenza-related encounters among vaccinees.
Statins are frequently used in the elderly to reduce the risk of cardiovascular disease [1] [2] [3] [4] [5] . Multiple studies have reported that statins may have clinically relevant antiinflammatory effects independent of their lipid-lowering effects [6] [7] [8] [9] [10] [11] [12] . It is possible that these immunomodulatory effects could impair the immune response to influenza vaccination [12] [13] [14] [15] . Interestingly, studies have also suggested that statins may decrease the risk of pneumonia and severe influenza outcomes, perhaps by reducing levels of inflammatory cytokines [16] [17] [18] [19] [20] [21] [22] .
Recent studies have raised concern that the immunogenicity and effectiveness of inactivated influenza vaccines may be lower among statin users [13, 14] . In a post hoc analysis of data from a randomized clinical trial, Black and collaborators evaluated the effect of statins on the immune response to inactivated influenza vaccines and found significantly lower hemagglutination inhibition (HI) titers to vaccine antigens among patients who had received statins from 28 days before to 22 days after vaccination. Among statin users, HI titers for the 3 vaccine antigens were 38% to 67% lower than among nonusers [13] . A 9-season retrospective cohort study found that influenza vaccine effectiveness (VE) during periods of widespread influenza circulation was 18% lower for participants who had >1 month of statin therapy prior to vaccination compared to nonusers [14] . A test-negative design study of influenza VE found an adjusted VE against influenza A(H3N2) infection of -21% (95% CI, -85% to 20%) among statin users and 45% (95% CI, 27% to 59%) among nonusers. These investigators found significant effects among users of nonsynthetic but not among synthetic statin users; no dose-effect response was noted [15] .
Given the limited published data, we conducted a retrospective cohort study to evaluate the effects of statins, including potential differences by statin type and dose, on the risk of influenza-related outcomes among Medicare beneficiaries aged >65 years who received influenza vaccination at community pharmacies [23, 24] .
METHODS

Data Sources
Medicare administrative files were the primary data source. Medicare provides health insurance coverage to approximately 49 million US residents aged >65 years, as well as to approximately 9 million beneficiaries who are disabled or have end-stage renal disease [14] . The files include data on enrollment, inpatient and outpatient care, physician office visits, and prescription drugs. Respiratory sample data were drawn from the National Respiratory and Enteric Virus Surveillance System [25] .
Participants
The study population consisted of Medicare beneficiaries aged >65 years who received high-dose (HD) or standard-dose (SD) influenza vaccines at community pharmacies from August through January of each influenza season in the study period, defined as 1 August 2010 through 1 August 2015. We restricted enrollment to beneficiaries vaccinated at pharmacies because previous studies demonstrated this restriction produced vaccinated cohorts balanced for factors associated with increased risks for serious complications of influenza infection [23, 24] . Beneficiaries were included for each season in which they received a vaccination [23, 24] . Vaccinations were identified using Healthcare Common Procedure Coding System (HCPCS) and Current Procedural Terminology (CPT) codes for highdose (CPT 90662); trivalent, standard-dose (CPT 90654, 90656-90661, 90673, and 90724; HCPCS Q2034-Q2039); and quadrivalent, standard-dose influenza vaccinations (CPT 90630, 90686, and 90688). Beneficiaries who received more than 1 vaccine type on the same date were excluded.
We required continuous enrollment in fee-for-service Medicare Parts A (hospitalization), B (outpatient medical care), and D (prescription drugs) for at least 1 year prior to vaccination to permit the identification of chronic medical conditions. Participants whose Medicare eligibility depended on disability or end-stage renal disease prior to age 65 were excluded [23, 24] . Beneficiaries enrolled in Medicare Part C (ie, Medicare advantage plans) were excluded because their medical encounters may not be reliably captured in claims data [23] . Additionally, beneficiaries were excluded if they resided in a nursing home or skilled nursing facility (SNF), received hospice care or chemotherapy, were diagnosed with human immunodeficiency virus or cancer other than skin cancer, or underwent organ transplant in the year prior to vaccination [26] . Medical condition exclusion criteria were identified using HCPCS, CPT, or International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes.
As statins are prescribed specifically to treat persons with hyperlipidemia to prevent complications of atherosclerotic cardiovascular disease, which may be associated with more serious complications of influenza, we excluded beneficiaries who received a diagnosis of atherosclerotic cardiovascular disease in the year prior to vaccination (Supplementary Table 1) .
Study Outcomes
The primary outcome was a community-based physician office visit or hospital outpatient visit that contained a claim for a rapid influenza diagnostic test (CPT code 87804) followed by a claim for a therapeutic course of oseltamivir (75 mg twice daily for 5 days) prescribed within 2 days of the test claim, referred to as "influenza-related office visits" [23] . The secondary outcome was a hospitalization or emergency department visit with an ICD-9-CM code for influenza (codes 487.xx and 488.xx), referred to as "influenza hospitalizations. "
We focused on high influenza circulation periods to increase specificity of our outcome [23, 24] . Each week in an influenza season was classified as a high-, medium-, or low-intensity influenza circulation period within each geographic region of the United States, as defined by the Department of Health and Human Services (HHS). These periods were defined as weeks in which the proportion of respiratory samples that tested positive for influenza within that season and region was above the 75th percentile, within the 55th and 75th percentile, or below the 55th percentile, respectively [23] .
Statin Exposure
Participants were classified as statin users or nonusers. Statin users were defined as beneficiaries with a sufficient supply of statins to cover the 15 days before through 15 days after vaccination, with a maximum allowable gap of 2 days, and who received at least 2 prescriptions of statins in the period from 6 months before to 15 days after vaccination, with a medication possession ratio of ≥0.8 [27] . Nonusers were defined as beneficiaries with no evidence of receiving statins during the period extending from 6 months before to 15 days after vaccination. Beneficiaries who did not meet the criteria for either group were excluded.
Person-Time Under Observation
Follow-up began 14 days after vaccination to permit development of vaccine-specific immunity [28] . It ended when one of the following was reached: a study outcome of interest; disenrollment from Medicare Parts A, B, or D; admission to a SNF or nursing home; transfer to hospice care; end of influenza season; or death.
Control for Confounding
Data on demographics, socioeconomic status, medical encounter history, medical conditions, and health status were collected for each beneficiary during the year prior to vaccination [29, 30] . We used a combination of exact matching and propensity score matching to adjust for potential confounders [31, 32] . Propensity scores (the probability of statin use conditional on the baseline characteristics described in Table 1 ) were calculated using a logistic regression model, with statin use as the dependent variable. For each statin user, we first identified a group of nonusers who were identical by vaccine type, sex, age group (65-69, 70-74, 75-79, 80-84, and 85+ years), and HHS region of residence and then selected the nonuser with the nearest propensity score [31] . Balance in baseline covariates between the cohorts was assessed using standardized mean differences (SMDs). We considered SMDs of <0.1 to represent a negligible imbalance [33] .
Statistical Analyses
Rates for each study outcome in the low-, medium-, and high-intensity influenza periods were calculated as the number of outcomes divided by person-time in weeks. We used 3 Poisson regression models to estimate rate ratios between statin users and nonusers (model specifications provided in the Supplementary Methods). The first model adjusted for influenza season to account for differences in influenza circulation by season. The second model included all covariates used for matching (Table 1 ) in addition to season. In the third model, an interaction term between season and statin exposure was added to model 2 to determine if associations between statin use and outcome risks varied by season. The Akaike information criterion was used to evaluate model fit [34] . Two-tailed P values ≤ .05 were considered statistically significant.
We conducted several additional analyses. To determine if statin effects varied by receipt of HD or SD vaccine, we fit a model including an interaction for vaccine type and statin exposure. We also examined the effect of synthetic (atorvastatin, fluvastatin, rosuvastatin) vs nonsynthetic (simvastatin, pravastatin, lovastatin, and pitavastatin) statins and intensity of statin treatment exposure on influenza-related outcomes (Supplementary Table 2 ). For the statin-type analysis, the statin user cohort was split into synthetic and nonsynthetic statin cohorts [15] . In the statin-intensity analysis, the statin user cohort was split into low-, moderate-, and high-intensity statin cohorts based on active ingredient and prescribed dose [35] . To investigate the effect of the relationship between statin type and intensity, we fit a model comparing users of different statin type and intensity combinations (Supplementary Table 2 ). In a post hoc analysis, the statin-intensity analysis was repeated with cohorts weighted with stabilized inverse probability of treatment weights (IPTWs) to address residual imbalances found in the statin-intensity cohorts (Supplementary Table 3 ) [31] .
To determine if our findings might reflect the effect of persistent use of a common medication rather than statin-specific effects, we performed "negative exposure" analyses [36] . These analyses replicated the study methodology for the primary and secondary outcomes using alternate exposures in place of statin use to determine if observed differences were due to bias from unmeasured confounders [36] . Null results would suggest lack of confounding. Negative exposures considered were hydrochlorothiazide medications (HCTZs) not combined with another drug in a single pill and proton pump inhibitors (PPIs).
Analyses were conducted using R 3.2.0 (R Foundation for Statistical Computing, Vienna, Austria) and SAS, v. 9.4 (SAS Institute Inc., Cary, North Carolina). All analyses were performed with deidentified data collected for administrative purposes by the Centers for Medicare and Medicaid Services.
RESULTS
More than 72 million Medicare beneficiaries received influenza vaccinations during the study period. After applying inclusion criteria, 8% of vaccinees remained in the study. Of these, 28% were classified as statin users, 55% as nonusers, and 17% as neither ( Figure 1 ). Prior to matching, the statin user and nonuser cohorts were imbalanced (SMD > 0.1) by frequency of outpatient visits; all physician visits; diabetes severity; and prevalence of hypercholesterolemia, hypertension, and chronic kidney failure. After matching, cohorts were well balanced on all defined covariates (Table 1 ) and on the proportion of beneficiaries vaccinated in the prior season (Supplementary Table 4) .
During 17 110 929 person-weeks of observation, 2419 influenza-related office visits occurred among statin users (1.41 cases/10 000 person-weeks); 2235 visits occurred among nonusers during 17 063 761 person-weeks (1.31 cases/10 000 person-weeks) in the matched cohorts ( Table 2 ). The risk difference ranged from -0.02 to 0.23 per 10 000 person-weeks depending on season severity (Supplementary Table 5 ). We identified 1316 influenza hospitalizations in statin users during 17 151 832 person-weeks (0.77/10 000 person-weeks) and 1197 influenza hospitalizations in nonusers during 17 129 468 person-weeks (0.70/10 000 person-weeks), for a risk difference ranging from -0.04 to 0.13 (Supplementary Table 5 ). Results from the 3 Poisson models are presented in Table 3 . Statin use was associated with small but statistically significant increased relative risks (RRs) for influenza office visits (RR, 1.09; 95% confidence interval [CI], 1.03 to 1.15) and influenza hospitalizations (RR, 1.10; 95% CI, 1.02 to 1.19; Figure 2 ). We found no evidence that statin associations varied by receipt of HD compared to SD vaccine (interaction P values ranged from .11 to .4; Supplementary Table 6 ). We did not find significant differences in risk of either influenza outcome when we compared synthetic and nonsynthetic statin use (Figure 2) . Use of high-intensity statins was associated with a significantly elevated risk of influenza-related visits compared to all other use intensity categories (Table 4) . Moderate-intensity use was associated with an increased risk compared to nonuse. However, low-intensity use was not associated with differential risk when compared (Figure 2 ). Similar results were found in an IPTWweighted analysis (Table 4) . Using receipt of hydrochlorothiazide medications as a negative exposure, we found no associations with either influenza-related outcome (Supplementary Table 7 ). However, use of PPIs was significantly associated with influenza office visits (RR, 1.21; 95% CI, 1.11 to 1.31) and influenza hospitalization (RR, 1.19; 95% CI, 1.06 to 1.32; Supplementary Table 8) .
DISCUSSION
In a 5-season study that enrolled more than 2.8 million Medicare beneficiaries aged >65 years, we found that those exposed to statins around the time of vaccination had small (RD per 10 000 person-weeks ranged from -0.02 to 0.23 for office visits and from -0.04 to 0.13 for hospitalizations) but significant increased risks for influenza-related outcomes compared to nonusers (Supplementary Table 5 ). Over the study period, approximately 178 additional influenza-related office visits and 117 additional influenza-related hospitalizations in the study population may be attributed to statin use at the time of vaccination (Supplementary Table 5 ). High-intensity statin users had significantly higher risks than nonusers for both outcomes (Table 4) , suggesting the possibility of a dose effect. However, results for the comparison between moderate and low-intensity users with nonusers were not consistent. We found no significant differences in influenza risks between synthetic and nonsynthetic statin users. Risk for influenza outcomes was elevated for all statin type and intensity combinations, although differences were not consistently significant (Figure 2 ). The majority of synthetic and nonsynthetic statin use was of moderate intensity. In a comparison of those 2 groups, we found no significant differences in influenza risk, suggesting no effect by statin type.
Our results are consistent with the direction of the effects identified by Black et al, who found 38%-62% lower HI titers, depending on influenza strain, in statin users compared to nonusers. Our findings of increased risks of approximately 10% among statin users are consistent with, albeit smaller in magnitude than, the lower HI titers observed among statin users by Black et al. While Black et al. found that patients who received nonsynthetic statins had higher HI titers than those who received synthetic statins [13] , we found no significant differences in influenza risk between synthetic and nonsynthetic statin users. To account for the high correlation between type and intensity of statins, we analyzed statin treatment by combinations of type and intensity. Our results suggest significant differences in risk by statin intensity but not statin type (Table 4) . Because Black et al. did not collect data on statin intensity, their findings may be confounded by statin intensity.
Direct comparisons between our findings and those from studies that included an unvaccinated group are not possible. In Medicare data, lack of a claim for influenza vaccination cannot be used to establish that a beneficiary did not receive a vaccination because it is possible that a claim was not submitted or that a vaccine claim was submitted to another payer. Thus, we cannot present VE estimates. However, we can make several observations. Omer et al. found a substantial reduction in influenza VE among statin users compared to nonusers [14] . While the Omer et al. study did not directly compare vaccinated statin users to nonusers, they did report unadjusted incidence rates for both groups. Applying the ratio-of-ratios approach used by Omer, we calculated that the ratio of the unadjusted risk of medically attended acute respiratory illness (MAARI) among vaccinated statin users and nonusers was 1.08 [14] , which is consistent with our findings of 9%-10% differences in risk, despite the different b SMD values ≥0.1 indicate that the 2 groups are imbalanced on the specified covariates.
c The aDCSI score assigns points for the presence of retinopathy, nephropathy, neuropathy, cerebrovascular diseases, peripheral vascular diseases, and metabolic diseases.
d COPD complexity is assigned based on the presence and severity of COPD-related diagnoses. In a 10-season study that enrolled 3285 participants aged ≥45 years, McLean et al. found that VE for real-time polymerase chain reaction-confirmed influenza outpatient visits was substantially and significantly lower in statin users for influenza A(H3N2) virus infections. However, VE against influenza A(H1N1)pdm09 or B infections did not differ by statin use [15] . Since Medicare claims data do not provide this information, we cannot compare statin effects by virus type or subtype. However, Table 5 ).
We were unable to distinguish between the effect of statins on vaccine effectiveness vs the direct effect of statins on risk of influenza [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Only 8.6% of all beneficiaries in the study switched their statin-use status post-vaccination (Supplementary Table 10 ), reflecting a lack of power to separate these 2 effects. As a sensitivity analysis, we compared statin users and nonusers who did not switch their statin status post-vaccination and found rate ratio estimates consistent with those of the primary analysis (Supplementary Table 11 ).
Our study had limitations, some of which we noted in previous publications that used similar methods [23, 24] . In addition, the statin user and nonuser populations may have differed by unmeasured covariates, including body mass index, diet, smoking status, and social contacts. In an effort to minimize bias potentially associated with unmeasured confounders, including being ambulatory, we restricted all analyses to beneficiaries vaccinated at community pharmacies [23, 24] . To further address potential unmeasured confounders, such as those reflected by chronic use of common medications, we performed negative exposures analyses with HCTZs and PPIs. We found no association between HCTZs and influenza outcomes. A significant association with PPIs was found, which might suggest the possibility of residual bias or unmeasured confounders. In retrospect, however, our choice of PPIs as a negative exposure may not have been ideal. PPIs have multiple effects beyond those on gastric pH, which may affect susceptibility to pneumonia and thus the diagnosis of infection with specific respiratory pathogens [37] [38] [39] [40] . Thus, further investigation might be needed to determine whether this is a real effect or a result of unmeasured confounding. The cohort restrictions we used to reduce confounding, including exclusion of beneficiaries with cardiovascular conditions, may limit the generalizability of our findings; whether the associations we observed are similar in less healthy beneficiaries is unknown. Only cases that occurred during high influenza circulation periods, which are more likely to be associated with influenza infections, were included for all analyses. a Each week of an influenza season for each region was classified as high, medium, or low influenza intensity when the proportion of respiratory samples that tested positive for influenza was above the 75th percentile, within the 55th and 74th percentile, or below the 55th percentile, respectively. b Statin nonusers were used as the reference group for raw rate ratio calculations. The multivariate Poisson models in this study adjusted for all the variables used in the matching process (see Table 1 ). The multivariate Poisson model without season interaction is the best fitting model for the influenza office visit outcome based on its AIC value.
Abbreviations: AIC, Akaike information criterion; CI, confidence interval. a Only cases that occurred during high influenza circulation periods, which are more likely to be associated with influenza infections, were included for all analyses. In summary, we found small associations between statin use and relative risks for influenza office visits and hospitalizations among vaccinated Medicare beneficiaries, consistent with the direction of results from an immunogenicity trial but of smaller magnitude [13] . Our findings suggest that receipt of statins around the time of influenza vaccination does not substantially affect the risk of influenza-related medical encounters among vaccinated Medicare beneficiaries. These findings should be interpreted in the context of the well-established benefits of statins for reducing the risk of cardiovascular outcomes. Only cases occurring during high influenza circulation periods, which are more likely to be associated with influenza infections, were included for all analyses. Propensity scores were used to derive inverse probability of treatment weights, which were used to weight the analysis cohorts.
Abbreviation: CI, confidence interval.
